英文名稱 | CPI-0610 |
---|---|
中文名稱 | CPI-0610 |
CAS號(hào) | 1380087-89-7 |
分子式 | C20H16ClN3O2 |
分子量 | 365.81 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
5 mg | In-stock | ¥1100.00 | 登錄后可見(jiàn) | |
10 mg | In-stock | ¥2100.00 | 登錄后可見(jiàn) |
英文名稱 | CPI-0610 |
---|---|
中文名稱 | CPI-0610 |
CAS號(hào) | 1380087-89-7 |
分子式 | C20H16ClN3O2 |
分子量 | 365.81 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.